Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CTIM-76 |
Synonyms | |
Therapy Description |
CTIM-76 is a bispecific T-cell engager that targets CLDN6 and CD3, potentially leading to killing of tumor cells expressing CLDN6 (Cancer Res (2023) 83 (7_Supplement): 1865). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CTIM-76 | CTIM76|CTIM 76 | CD3 Antibody 99 CLDN6 Antibody 8 | CTIM-76 is a bispecific T-cell engager that targets CLDN6 and CD3, potentially leading to killing of tumor cells expressing CLDN6 (Cancer Res (2023) 83 (7_Supplement): 1865). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06515613 | Phase I | CTIM-76 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Recruiting | USA | 0 |